1. Home
  2. HSPO vs IMAB Comparison

HSPO vs IMAB Comparison

Compare HSPO & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSPO
  • IMAB
  • Stock Information
  • Founded
  • HSPO 2014
  • IMAB 2014
  • Country
  • HSPO United States
  • IMAB United States
  • Employees
  • HSPO N/A
  • IMAB N/A
  • Industry
  • HSPO Blank Checks
  • IMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • HSPO Finance
  • IMAB Health Care
  • Exchange
  • HSPO Nasdaq
  • IMAB Nasdaq
  • Market Cap
  • HSPO 91.5M
  • IMAB 87.2M
  • IPO Year
  • HSPO 2022
  • IMAB 2020
  • Fundamental
  • Price
  • HSPO $11.74
  • IMAB $0.96
  • Analyst Decision
  • HSPO
  • IMAB Strong Buy
  • Analyst Count
  • HSPO 0
  • IMAB 3
  • Target Price
  • HSPO N/A
  • IMAB $8.00
  • AVG Volume (30 Days)
  • HSPO 3.2K
  • IMAB 354.5K
  • Earning Date
  • HSPO 01-01-0001
  • IMAB 03-13-2025
  • Dividend Yield
  • HSPO N/A
  • IMAB N/A
  • EPS Growth
  • HSPO 2.63
  • IMAB N/A
  • EPS
  • HSPO 0.28
  • IMAB N/A
  • Revenue
  • HSPO N/A
  • IMAB $3,313,984.00
  • Revenue This Year
  • HSPO N/A
  • IMAB N/A
  • Revenue Next Year
  • HSPO N/A
  • IMAB N/A
  • P/E Ratio
  • HSPO $41.64
  • IMAB N/A
  • Revenue Growth
  • HSPO N/A
  • IMAB N/A
  • 52 Week Low
  • HSPO $10.77
  • IMAB $0.84
  • 52 Week High
  • HSPO $12.41
  • IMAB $2.00
  • Technical
  • Relative Strength Index (RSI)
  • HSPO 55.44
  • IMAB 43.19
  • Support Level
  • HSPO $11.68
  • IMAB $1.03
  • Resistance Level
  • HSPO $12.10
  • IMAB $1.10
  • Average True Range (ATR)
  • HSPO 0.14
  • IMAB 0.06
  • MACD
  • HSPO -0.00
  • IMAB -0.01
  • Stochastic Oscillator
  • HSPO 32.32
  • IMAB 7.58

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Share on Social Networks: